Patent intelligence · US
US 9089156
Reducing muscle soreness with glucosamine compositions
Reducing muscle soreness with glucosamine compositions
Patent details — US 9089156
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 28, 2015
- Expiration
- Jul 23, 2035
- Applicant
- Stokely-Van Camp, Inc.
- Claims
- 5
- CPC classes
- A61P, A61P21/02, A61P29/00
Quick answer
US 9089156 (Reducing muscle soreness with glucosamine compositions) is held by Stokely-Van Camp, Inc.. Status: granted. Granted Jul 28, 2015. Expires Jul 23, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Stokely-Van Camp, Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61P, A61P21/02, A61P29/00
More from Stokely-Van Camp, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12338437
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 12060558
Methods and compositions for treatment of cholesteryl ester storage disease
granted -
US 11873490
Antisense oligomers for treatment of conditions and diseases
granted -
US 11814622
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 11096956
Antisense oligomers and uses thereof
granted -
US 11083745
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome
granted -
US 10913947
Antisense oligomers for treatment of conditions and diseases
granted -
US 10683503
Antisense oligomers for treatment of conditions and diseases
granted
Frequently asked questions
What is US patent 9089156?
US 9089156 (Reducing muscle soreness with glucosamine compositions) is held by Stokely-Van Camp, Inc.. Status: granted. Granted Jul 28, 2015. Expires Jul 23, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9089156?
Stokely-Van Camp, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 14 pharmaceutical patents for this assignee.
When does US 9089156 expire?
Our index shows an expiration date of Jul 23, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.